A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Ipragliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2013 Results published in the Journal of Diabetes and its Complications.
- 08 Dec 2011 Results presented at the 21st World Diabetes Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History